Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Inhibikase Therapeutics, Inc. (IKT) is a Biotechnology company based in US with a market capitalization of $294.4M. Free cash flow was negative at -$27.8M. This page tracks IKT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 15 employees · IPO Dec 23, 2020
Valuation
Valuation & price
$1.73as of May 17, 2026· -19.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.70
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$294.4M
Market cap
—
Revenue growth (YoY)
-5127.8%
Gross margin
-$27.8M
Free cash flow (USD)
-$178.8M
Net debt
Net cash position
41.7%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2023
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Inhibikase Therapeutics, Inc.'s market cap?
Inhibikase Therapeutics, Inc. (IKT) has a market capitalization of $294.4M.
What is IKT's P/E ratio?
A meaningful P/E ratio is not available for IKT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is IKT's price-to-book (P/B) ratio?
IKT trades at 1.70 times book value per share.
Are insiders buying IKT stock?
SEC Form 4 filings show no open-market insider buys at Inhibikase Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.